• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Editorial: Special issue: Non-alcoholic fatty liver disease: From molecular basis to therapeutic advances.社论：特刊：非酒精性脂肪性肝病：从分子基础到治疗进展
Metabol Open. 2023 Jan 13;17:100229. doi: 10.1016/j.metop.2023.100229. eCollection 2023 Mar.
2
Quantitative assessment of self-management in patients with non-alcoholic fatty liver disease: An unmet clinical need.非酒精性脂肪性肝病患者自我管理的定量评估：未满足的临床需求。
World J Gastroenterol. 2024 Jul 7;30(25):3143-3146. doi: 10.3748/wjg.v30.i25.3143.
3
[Research advances in nonalcoholic fatty liver disease and alcoholic liver disease in 2016].2016年非酒精性脂肪性肝病和酒精性肝病的研究进展
Zhonghua Gan Zang Bing Za Zhi. 2017 Mar 20;25(3):181-186. doi: 10.3760/cma.j.issn.1007-3418.2017.03.005.
4
[Effect of liraglutide in treatment of non-alcoholic fatty liver disease: mechanism of action and research advances].利拉鲁肽治疗非酒精性脂肪性肝病的作用：作用机制及研究进展
Zhonghua Gan Zang Bing Za Zhi. 2017 Jun 20;25(6):473-476. doi: 10.3760/cma.j.issn.1007-3418.2017.06.018.
5
[Advances in the pathogenesis of non alcoholic fatty liver disease].[非酒精性脂肪性肝病发病机制的研究进展]
Orv Hetil. 2017 Jun;158(23):882-894. doi: 10.1556/650.2017.30775.
6
[Non-alcoholic fatty liver disease and steatohepatitis].[非酒精性脂肪性肝病和脂肪性肝炎]
Orv Hetil. 2013 Jul 21;154(29):1124-34. doi: 10.1556/OH.2013.29626.
7
[Non alcoholic fatty liver disease: a new risk factor for cardiovascular disease?].[非酒精性脂肪性肝病：心血管疾病的一个新危险因素？]
Tunis Med. 2013 Mar;91(3):171-4.
8
Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates.非酒精性脂肪性肝病的药物治疗：新兴靶点与候选药物
Biomedicines. 2022 Jan 26;10(2):274. doi: 10.3390/biomedicines10020274.
9
Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD).社论：用代谢相关脂肪性肝病（MAFLD）取代非酒精性脂肪性肝病（NAFLD）术语的国际共识建议。
Med Sci Monit. 2021 Jul 12;27:e933860. doi: 10.12659/MSM.933860.
10
Treatment of patients with non-alcoholic fatty liver disease: current views and perspectives.非酒精性脂肪性肝病患者的治疗：当前观点与展望
Dig Liver Dis. 2006 Nov;38(11):789-801. doi: 10.1016/j.dld.2006.04.009. Epub 2006 Jun 5.

引用本文的文献

1
The effects of medicinal and food homologous substances on blood lipid and blood glucose levels and liver function in patients with nonalcoholic fatty liver disease: a systematic review of randomized controlled trials.药食同源物质对非酒精性脂肪肝患者血脂、血糖及肝功能的影响：一项随机对照试验的系统评价。
Lipids Health Dis. 2023 Aug 29;22(1):137. doi: 10.1186/s12944-023-01900-5.

本文引用的文献

1
Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review.内皮细胞功能障碍与非酒精性脂肪性肝病（NAFLD）：简要综述。
Cells. 2022 Aug 12;11(16):2511. doi: 10.3390/cells11162511.
2
Effect of 8 Weeks milk thistle powder (silymarin extract) supplementation on fatty liver disease in patients candidates for bariatric surgery.8周水飞蓟粉（水飞蓟素提取物）补充剂对肥胖症手术候选患者脂肪肝疾病的影响。
Metabol Open. 2022 May 21;14:100190. doi: 10.1016/j.metop.2022.100190. eCollection 2022 Jun.
3
Liver steatosis, cardiac and renal fibrosis, and hypertension in overweight rats: Angiotensin-(3-4)-sensitive hepatocardiorenal syndrome.超重大鼠的肝脂肪变性、心脏和肾脏纤维化以及高血压：血管紧张素-(3-4)敏感型肝心肾综合征。
Metabol Open. 2022 Mar 18;14:100176. doi: 10.1016/j.metop.2022.100176. eCollection 2022 Jun.
4
SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection.钠-葡萄糖共转运蛋白 2 抑制剂在非酒精性脂肪性肝病中的作用：超越糖尿病和心脏保护的角色。
Int J Mol Sci. 2022 Mar 13;23(6):3107. doi: 10.3390/ijms23063107.
5
Acute intermittent hypoxia drives hepatic lipogenesis in humans and rodents.急性间歇性低氧可促进人类和啮齿动物的肝脏脂肪生成。
Metabol Open. 2022 Mar 14;14:100177. doi: 10.1016/j.metop.2022.100177. eCollection 2022 Jun.
6
Noninvasive assessment of fibrosis among patients with nonalcoholic fatty liver disease [NAFLD].非酒精性脂肪性肝病（NAFLD）患者纤维化的无创评估
Metabol Open. 2022 Jan 5;13:100158. doi: 10.1016/j.metop.2021.100158. eCollection 2022 Mar.
7
Hepatic P38 Activation Modulates Systemic Metabolism Through Fgf21-Mediated Interorgan Communication.肝脏P38激活通过Fgf21介导的器官间通讯调节全身代谢。
Diabetes. 2021 Oct 21. doi: 10.2337/db21-0240.
8
DRAK2-SRSF6-regulated RNA alternative splicing is a promising therapeutic target in NAFLD/NASH.DRAK2-SRSF6调控的RNA可变剪接是NAFLD/NASH中一个有前景的治疗靶点。
Metabol Open. 2021 Dec 8;13:100157. doi: 10.1016/j.metop.2021.100157. eCollection 2022 Mar.
9
Emerging roles for stress kinase p38 and stress hormone fibroblast growth factor 21 in NAFLD development.应激激酶p38和应激激素成纤维细胞生长因子21在非酒精性脂肪性肝病发展中的新作用。
Metabol Open. 2021 Nov 30;12:100153. doi: 10.1016/j.metop.2021.100153. eCollection 2021 Dec.
10
Protective effects of cerium oxide nanoparticles in non-alcoholic fatty liver disease (NAFLD) and carbon tetrachloride-induced liver damage in rats: Study on intestine and liver.氧化铈纳米颗粒对大鼠非酒精性脂肪性肝病（NAFLD）及四氯化碳诱导的肝损伤的保护作用：肠道与肝脏的研究
Metabol Open. 2021 Nov 18;12:100151. doi: 10.1016/j.metop.2021.100151. eCollection 2021 Dec.

Editorial: Special issue: Non-alcoholic fatty liver disease: From molecular basis to therapeutic advances.

作者信息

Nasiri-Ansari Narjes, Kassi Eva

机构信息

Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527, Athens, Greece.

Endocrine Unit, 1st Department of Propaedeutic Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, 11527, Athens, Greece.

出版信息

Metabol Open. 2023 Jan 13;17:100229. doi: 10.1016/j.metop.2023.100229. eCollection 2023 Mar.

DOI:10.1016/j.metop.2023.100229
PMID:36686606
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9853362/
Abstract
摘要